Updated: July 1, 2022
PHARMAC has now implemented widened funded access to the first line UTI treatment MacroBID® modified release nitrofurantoin capsules. MacroBID® is a modified release nitrofurantoin containing nitrofurantoin macrocrystals and nitrofurantoin monohydrate for the treatment of acute, symptomatic uncomplicated urinary tract infections (UTIs). The widened funding now aligns with New Zealand guidelines on Antibiotic use . Te Arai BioFarma Chairman Dr. Lance Gravatt stated "This is an important funding decision to ensure that rural New Zealanders in particular have ready access to effective first line UTI treatment. With the ongoing pressure of antibiotic resistance, strong antimicrobial stewardship decisions such as this are crucial."
Comments